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Abstract Based on their mode of action, it is reasonable
to expect that the combination therapy of aspirin and a
vitamin K antagonist (VKA) may be more beneficial in
preventing (athero) thrombotic complications in high-risk
patients for cardiovascular events. However, there is no
consensus about additional aspirin use in the most common
indications for VKA or the use of VKAs to be added to the
most common aspirin indications. The variation in clinical
outcomes and bleeding complications suggests that
extrapolating from one indication to another may not be
appropriate. So far, decisions about the combined use of
aspirin and VKA are individualized in the absence of
adequate data. Only in patients with mechanical heart
valves the benefits and safety of combining aspirin with
VKA therapy seems obvious. In patients with peripheral
artery disease no beneficial effect was noted for the com-
bination therapy, perhaps with an exception of those with
graft failure. For all other clinical situations, this is unclear
and should be avoided.
Keywords: Antiplatelet therapy  Anticoagulant therapy 
Vitamin K antagonists  Combination therapy 
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Introduction
Platelets anti-aggregation drugs reduce cardiovascular
events in nearly all groups of patients with clinical mani-
festations of atherosclerosis, including coronary artery,
cerebrovascular and peripheral artery disease [1, 2].
However, the cardiovascular risk remains elevated even if
patients are on optimal secondary preventive treatments
[1]. On the other hand the use of vitamin K antagonists
(VKAs) remains the most efficacious antithrombotic regi-
men for the primary and secondary prevention of
cardioembolic stroke in high-risk patients with atrial
fibrillation, prosthetic valves and for the prevention and
treatment of venous thromboembolism. However, their safe
use requires intensive dose monitoring.
The combination therapy of aspirin and VKAs is fre-
quently considered in various clinical settings and is
increasingly applied in high risk patients because of (a) the
expected additional protection against coronary artery dis-
ease to stroke prevention among patients with atrial
fibrillation who are exposed to a high risk for future coronary
diseases, (b) additional further stroke-preventive efficacy to
usual international normalized ratio (INR) targets for high-
risk groups and (c) the supposed reduced risk of haemorrhage
by using lower INR targets while preserving efficacy.
Methods
The purpose of this article is to discuss the efficacy and
safety of the dual of aspirin and VKAs prescription in
clinical settings of secondary prevention. We therefore
performed a computerized search via PubMed/MedLine
and the Cochrane database using the MeSH terminology.
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coumarin, anticoagulant, vitamin K antagonist, dual ther-
apy, combination therapy, atrial fibrillation, myocardial
ischemia, heart valve diseases, cerebrovascular disorders,
peripheral artery disease, atherosclerosis and venous
thromboembolism.
Results
Clinical settings with an indication for a VKA:
is adding aspirin beneficial?
Atrial fibrillation
The risk of stroke in people with atrial fibrillation (AF) is
3–5% per year, although this may vary according to other
risk factors evaluated by the CHADS2-score (a clinical
prediction rule for estimating the risk of stroke in patients
with AF) [3]. The risk of stroke in people with AF who
have had a previous transient ischemic attack (TIA) may
be as high as 12% per year. Anticoagulants have been
proven to be more effective in prevention of ischemic
stroke in people with AF than aspirin [4].
The current guideline recommends anticoagulation with a
VKA in patients with persistent or paroxysmal AF at high risk
of stroke (i.e., having any of the following features: prior
ischemic stroke, transient ischemic attack, or systemic embo-
lism, age [ 75 years, moderately or severely impaired left
ventricular systolic function and/or congestive heart failure,
history of hypertension, or diabetes mellitus, corresponding to
a CHADS2-score of 3 or more). In patients between age 65 and
75 years, in the absence of other risk factors, who are at
intermediate risk of stroke (i.e. CHADS2-score B 2) anti-
thrombotic therapy with either a VKA or aspirin is
recommended. In patients with persistent AF or paroxysmal
AF below the age of 65 years who have no other risk factors
(CHADS2-score = 0), aspirin is recommended [5].
Although no additional benefit has been demonstrated
from combining aspirin and a VKA for stroke prophylaxis
in AF patients, concomitant conditions such us coronary
artery disease (CAD), peripheral artery and cerebrovascu-
lar disease are indications for aspirin. However, there is
insufficient evidence to justify the routine use of anti-
platelet agents in addition to a VKA in these situations,
primarily, because safety data of dual therapy are lacking:
Table 1 shows the relative risk and the bleeding risk of the
concomitant use of both aspirin and VKAs in patients with
AF in different conducted studies. Lechat et al. found that
there was no statistical difference between the groups for
the primary endpoints, but haemorrhagic complications
were significantly more frequent in the aspirin group [8].
Gullov et al. found in the AFASAK 2 trial that fixed-mini-
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associated with both minor and major bleeding [7]. In a
recent study with 3,566 patients with chronic AF, receiving
warfarin therapy targeted to achieve an INR of 2.0–3.0,
patients who were receiving concomitant aspirin (100 mg/
day) had a more than 2-fold increased risk for major
bleeding [10].
The trial conducted by Edvardsson et al. [9] on the effect
of low-dose warfarin and aspirin vs. no treatment on stroke
in a medium-risk population with AF was inconclusive, but
consistent with a small beneficial effect of the combination
therapy for reduction of stroke and major vascular events.
However this slight advantage was accompanied with
significantly increased risk of bleeding.
In the SPAFI trial [6] low-intensity, fixed-dose warfarin
plus aspirin was insufficient for stroke prevention in
patients with non-valvular AF at high-risk for thrombo-
embolism; adjusted-dose warfarin (target INR 2.0–3.0)
reduced stroke in high-risk patients importantly. In these
highly selected high-risk patients with AF major bleeding
occurred at comparable rates with both treatments.
In conclusion none of the conducted studies demon-
strated a benefit of the antiplatelet and VKAs therapy
combination. This combination therapy provides no better
prophylaxis against stroke than a VKA alone while mild
and severe haemorrhagic complications are significantly
more frequent.
Valvular heart disease
Patients with prosthetic heart valves are at increased risk
for valve thrombosis and valve related thromboembolism
[11–13]. Life-long oral anticoagulation is considered to be
essential for the prevention of thromboembolic events after
implantation of a mechanical heart valve. Nevertheless,
thromboembolic events occur after mechanical valve
replacement in approximately 2–4% of patients per year
despite the use of a VKA [14]. The addition of antiplatelet
drugs to VKAs has been suggested and used to minimize
this risk. An important issue is the effectiveness and safety
of this strategy.
In 2003 The Cochrane Collaboration has published a
review on the use of antiplatelet therapy and VKA in
patients with prosthetic heart valves [15]. The authors
reported that, compared to anticoagulation alone, the
addition of an antiplatelet agent reduced the risk of
thromboembolic events (odds ratio 0.39 (95% confidence
interval (CI): 0.28–0.56; P \ 0.00001)) and total mortality
(odds ratio 0.55 (95% CI: 0.40–0.77; P = 0.0003)). The
risk of major bleeding was increased when antiplatelet
agents were added to VKAs (odds ratio 1.66 (95% CI:
1.18–2.34; P = 0.003)). They concluded that adding anti-
platelet therapy to a VKA decreases the risk of systemic
embolism or death among patients with prosthetic heart
valves while the risk of major bleeding is increased with
antiplatelet therapy when added to a VKA.
The seventh ACCP conference on antithrombotic and
thrombolytic therapy recommends the use of aspirin (75–
100 mg/day) for patients who have mechanical heart
valves and additional risk factors such as AF, myocardial
infarction, left atrial enlargement, endocardial damage, and
low ejection fraction and for patients with mechanical
prosthetic heart valves who suffer from systemic embolism
despite a therapeutic INR [16].
In two more recently published meta-analyses, it was
definitely established that adding antiplatelet therapy,
especially low-dose aspirin, to a VKA decreases the risk of
systemic embolism or death among patients with prosthetic
heart valves [17, 18]. The risk of major bleeding is slightly
increased when adding antiplatelet therapy. Nonetheless,
the risk of bleeding appears to be diminished with the
lower doses of aspirin used in the more recent trials,
resulting in a favourable risk-to-benefit profile. Older trials
(Table 2) noted a significant increase in bleeding, partic-
ularly when high doses of aspirin were used (500 mg/day
or more) in combination with high-intensity of a VKA.
In conclusion, the shown data demonstrate that the
benefits of the combination of a VKA and aspirin outweighs
the bleeding risks and that adding antiplatelet therapy to a
VKA is more effective than anticoagulant therapy alone.
Venous thromboembolism
We found no trials evaluating the effects of Aspirin on top
of a VKA indicated for venous thrombosis. Prospective
randomised controlled clinical trials are therefore needed to
disclose this clinical issue.
Clinical settings in which aspirin is indicated: is adding
a VKA beneficial?
Non-cardioembolic stroke
Patients with limited cerebral ischemia of arterial origin are
at risk of serious vascular events (4–11% annually) [26,
27]. Aspirin is generally recommended in patients with
previous ischemic stroke or transient ischemic attack to
reduce the risk of recurrence. In general, it reduces the
incidence of major vascular events up to 20% [26–28].
VKAs are commonly recommended for the prevention
of recurrent stroke in patients with AF, but to date it has no
role in the prevention of non-cardioembolic ischemic
stroke. No trials were found comparing the combination of
aspirin and VKAs in combination to aspirin alone in the
prevention of stroke of presumed arterial origin. The
explanation for this may be that previous trials on VKA
monotherapy in cerebrovascular disease were not more
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efficacious than aspirin monotherapy, but were associated
with higher bleeding rates. In an update of a Cochrane
review in 2006, Algra et al. compared the efficacy and
safety of VKAs and antiplatelet therapy in the secondary
prevention of vascular events after cerebral ischemia of
presumed arterial origin [29]. They found insufficient
evidence to justify the routine use of medium intensity oral
anticoagulants (INR 2.0–3.6); more intense anticoagulation
(INR 3.0–4.5) was not safe because it yielded more major
bleeding complications and should therefore not be used in
this clinical setting. Even in the lowest intensity INR
range, addition of warfarin had no benefit above aspirin
alone. The WARSS study that compared the effect of
aspirin (325 mg) to that of warfarin at a dose adjusted to
produce an INR of 1.4–2.8 on recurrence of ischemic
stroke or death from any cause within 2 years. This study
showed no significant differences between the two
modalities in any of the outcomes measured [30].
In patients with non-cardioembolic stroke, oral antico-
agulants are no more effective than aspirin alone but cause
more bleeding. However data on the safety and effective-
ness of the dual therapy are lacking.
Myocardial infarction
Patients with a history of myocardial infarction are at
increased risk for recurrent infarction, stroke and death
[31, 32]. Although aspirin provides benefit preventing
recurrent myocardial infarction, the rates of recurrent
vascular events in patients with coronary artery disease
remains high [26]. There is evidence that a marked
thrombin generation persists for months after acute car-
diac events. Such a persistent stimulus to thrombosis even
in the presence of aspirin [33], may indicate a role for
anticoagulation therapy in this condition. This hypothesis
has led to the conduction of several trials testing the
combination therapy of aspirin and VKAs at varying
intensities. Although some studies have shown that addi-
tion of VKAs to aspirin decreases subsequent risk for
cardiovascular events, most studies did not (Table 3).
Because of the conflicting results of the trails so far,
different meta-analysis have been conducted in an attempt
to clarify this issue: Anand and Yusuf [2, 43] suggested
that high-intensity oral anticoagulation (INR [ 2.8) sig-
nificantly reduced cardiovascular complications but
increased bleeding rates compared with controls while the
combination of moderate-intensity oral anticoagulation
and aspirin was more effective and equally safe as aspirin
alone. Low-intensity oral anticoagulation (INR \ 2.0) in
combination with aspirin did not reduce cardiovascular
complications and increased bleeding compared to aspirin
alone. The results of the meta-analysis guided by Roth-
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syndrome, VKAs plus aspirin decreases the rate of myo-
cardial infarction or stroke more than aspirin alone [44].
Although the probability of major bleeding is also
increased, the benefits would far outweigh the bleeding
risks for many patients. On the other hand, the more recent
performed meta-analysis by Dentali et al. has shown no
benefits of combining aspirin and VKAs in patients with
coronary artery disease: there was no difference in all-
cause mortality with either treatment while the risk for
major bleeding was higher in the combination group [17].
The data in Table 3 show that adding VKAs to aspirin in
this patient category reduces ischemic events but increases
the rates of bleeding complications.
Peripheral artery disease (PAD)
Aspirin therapy, while having no effect on walking dis-
tance or symptom status, seems to modify the clinical
course of PAD. Large randomised trials have shown that
aspirin monotherapy delays the progression of established
PAD, as assessed by serial angiography, and decreases the
need for surgical revascularisation [45, 46]. Among
patients with AF and claudicatio intermittens, in whom
there is a particular risk of acute embolic lower limb
ischemia and stroke, randomised control trials and meta-
analyses have clearly indicated that anticoagulation with a
VKA (target INR 2.5–3.5) is superior to aspirin [47].
Previous data on dual therapy with aspirin and VKAs in
patients with PAD and sinus rhythm are conflicting, small,
heterogeneous and non-consistent. Many of these studies
focused on peripheral artery patency after vascular recon-
struction and were not designed to assess the potential
benefit of a VKA to reduce future cardiovascular outcomes
[36, 48–53]. As the rate of CV events is 5 times higher in
patients with PAD compared to patients without PAD and
moderate intensity VKA is effective in reducing CV events
in patients with CAD, there is a strong rationale for testing
the efficacy of long-term moderate intensity VKA (target
INR between 2 and 3) in addition to antiplatelet therapy to
prevent major vascular events in patients with PAD.
The conducted WAVE (the Warfarin and Antiplatelet
Vascular Evaluation)-trial [54], a large, international, ran-
domised clinical trial of patients at a high risk for vascular
diseases was designed to determine if moderate VKAs
anticoagulation (INR 2–3), in addition to antiplatelet
therapy is superior to antiplatelet therapy alone. The con-
clusion was that a VKA (targeting an INR range of 2–3)
added to antiplatelet therapy did not lower the rate of
cardiovascular events or death, but causes a 3.5-fold
increase in severe bleeding complications including cere-
bral haemorrhage. Life-threatening bleeding was seen in
4.0% on the combination therapy vs. 1.2% with aspirin
alone (P \ 0.001), effectively ruling out this dual approach
in PAD (Table 4).
Discussion
There is no consensus about combining VKAs and aspirin in
the most common indications for the use of anticoagulants
and aspirin. Based on their mode of action, it is reasonable to
expect that the combination therapy of aspirin and a VKA
may be more beneficial in preventing (athero) thrombotic
complications for cardiovascular events. Unfortunately, also
bleeding complications may overweigh the potential
advantage, so far the variations in outcomes suggest that
extrapolating from one indication to another may not be
appropriate.
Atrial fibrillation
The rationale for a dual therapy in AF is to reduce the risk of
bleeding in patients with AF by using low dose of VKAs
added to aspirin, to give additional stroke-preventive effi-
cacy to usual anticoagulation in patients considered to be at
high risk of thrombotic complications and the supposed
additional protection against coronary artery disease to
stroke prevention among patients with AF who are exposed
to a high risk for future coronary diseases. However, there is
insufficient evidence found to justify the concomitant use of
aspirin and a VKA: none of the conducted studies demon-
strated a benefit of the combination therapy. Therefore
clinicians should be aware of the risks of combining aspirin
and VKAs especially in our (ageing) population where the
co-prevalence of atherosclerosis and AF escalates. Aspirin
on top of a VKA provides no better prophylaxis against
stroke than a VKA alone while haemorrhagic complications
are significantly more frequent.
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cardiovascular causes
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RR = relative risk
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Prosthetic valves
In case of prosthetic valves we can state that at present-day
all the data analysing the combined use of aspirin and a
VKA show a significantly lower risk for thromboembolism
and that the benefits of the combination of a VKA and
aspirin outweighs the bleeding risks and should be partic-
ularly useful in patients with established cardiovascular
diseases, additional risk factors or recurrent embolism
despite a therapeutic INR. In fact, mechanical heart valves
remain the only clinical entity for which robust evidence is
demonstrated in randomised trials that adding antiplatelet
therapy to anticoagulant therapy is more effective than
anticoagulant therapy alone.
Venous thromboembolism
We found no study evaluating the effects of adding aspirin
to a VKA indicated for venous thromboembolism in case
of concomitant aspirin indication. It is reasonable, based on
their mode of action, to expect that the combination ther-
apy of aspirin and a VKA may be more beneficial in
preventing (athero) thrombotic complications in patients
with venous thromboembolism. The onset of a venous
thromboembolic event in patients who already take aspirin
as a prophylaxis because they are at moderate to high risk
for thromboembolic events, leads to the initiation of a
VKA. At the time of VKA initiation, aspirin should be
stopped because of the estimated higher risk of bleeding
and the lack of evidence to support the combined use of
aspirin and VKA in this patient category.
Non-cardioembolic stroke
Because of the lack of data from well-designed randomised
trials assessing the combined therapy in patients with non-
cardioembolic stroke and the finding that VKAs as
monotherapy are not more efficacious than aspirin, anti-
platelet agents remains nowadays the cornerstone of
secondary prevention. VKAs are commonly recommended
for the prevention of recurrent stroke in patients with AF,
but it has a lesser or no role in the prevention of non-
cardioembolic ischemic stroke. Given the risk/benefit ratio,
costs of monitoring therapy, and difficulty in maintaining a
therapeutic INR in a community setting, antiplatelet agents
are preferred over VKAs for prevention of recurrent
ischemic stroke. However VKAs should be considered in
patients who cannot tolerate antiplatelet agents [55, 56].
Coronary artery disease
Conflicting results are found on this issue: in some studies
clear reductions in total mortality, myocardial infarction,
and stroke occurred among patients treated with VKAs at
high intensity, although this therapy was also associated
with a significant increase in major bleeding. Conversely,
low-intensity anticoagulation in the presence of aspirin does
not confer any benefit over aspirin alone but still increases
major bleeding episodes. Moderate-intensity anticoagula-
tion reduced recurrent ischemic events and seems to be
more effective than aspirin alone and to be relatively safe.
This combination should be considered for high-risk
patients with CAD, including those who suffer a CV event
while receiving aspirin monotherapy. The potential benefits
of VKA therapy in reducing serious clinical events should
be weighed against life-threatening bleedings.
In a recent review Eijkelboom and Hirsh found that
adding VKA to aspirin reduces recurrent ischemic events
but does not reduce death and increases major bleeding
[57]. This increase in bleeding appears to be outweighed by
the reduction in recurrent myocardial infarction but the
potential for an increase in intracranial bleeding with the
combination of a VKA and aspirin is concerning.
Peripheral artery disease
Aspirin therapy is effective in preventing cardiovascular
events and death in patients with peripheral artery disease
[1]. No beneficial effect was noted for the combination
therapy of aspirin and VKA. In the WAVE trial, adding a
VKA to aspirin did not improve the clinical outcomes: the
primary outcome, a composite of MI, stroke or death was
not significantly different in the two groups but the rates of
bleedings and life-threatening bleeding was significantly
increased among patients treated with the combination of a
VKA and antiplatelet therapy.
However, this dual approach could be beneficial in
specific patient groups such as peripheral arterial recon-
structive surgery, recurrent graft failure and in cases of
limb salvage. Many randomised trials in patients with
various vascular disorders have studied the efficacy of
aspirin in the prevention of ischemic events. The Anti-
platelet Trialists’ Collaboration showed a beneficial effect
of aspirin therapy with no clear differences between types
of arterial disease. The efficacy of long-term treatment with
aspirin in patient’s who undergo infrainguinal bypass sur-
gery, however, has been studied in only a few randomised
trials [58–62]. The BOA (The Dutch Bypass Oral Antico-
agulants or Aspirin) trial showed that VKAs were better for
the prevention of infra-inguinal-vein-graft and for lowering
the rate of ischemic events. Aspirin was better for the
prevention of non-venous graft occlusion, and was asso-
ciated with fewer bleeding episodes [36]. What the efficacy
and safety of the combination therapy of aspirin and VKAs
in such specific subgroups with peripheral artery diseases is
not clear.
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Conclusion
This overview makes clear that only for patients with
mechanical heart valve the benefits and safety of combin-
ing aspirin with a VKA are clear. For patients with
peripheral artery disease no beneficial effect was noted for
the dual therapy. For other medical settings, there are no
adequate data to guide this common clinical conclusion.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Antithrombotic Trialists’ Collaboration (2002) Collaborative
meta-analysis of randomised trials of antiplatelet therapy for
prevention of death, myocardial infarction, and stroke in high-risk
patients. Br Med J 324(7329):71–86
2. Anand SS, Yusuf S (1999) Oral anticoagulants in patients with
coronary artery disease: a meta analysis. JAMA 282(21):2058–2067
3. Flemming KD, Brown RD Jr (2004) Secondary prevention strat-
egies in ischemic stroke: identification and optimal management
of modifiable risk factors. Mayo Clin Proc 79(10):1330–1340
4. Hart RG, Benavaente O, McBride R et al (1999) Antithrombotic
therapy to prevent stroke in AF: a meta-analysis. Ann Intern Med
131(7):492–501
5. Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning
WJ (2004) Antithrombotic therapy in atrial fibrillation: the sev-
enth ACCP conference on antithrombotic and thrombolytic
therapy. Chest 126(3 suppl):429S–456S
6. Stroke Prevention in Atrial Fibrillation Investigators (1996)
Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin
plus aspirin for high-risk patients with atrial fibrillation: stroke
prevention in atrial fibrillation III randomised clinical trial.
Lancet 348(9028):633–638
7. Gullov AL, Koefoed BG, Peterson P (1999) Bleeding during
warfarin and aspirin therapy, in patients with atrial fibrillation,
The AFASAK 2 study. Arch Intern Med 159(12):1322–1328
8. Lechat P, Lardoux H, Mallet A, Sanchez P, Derumeaux G,
Lecompte T et al (2001) Anticoagulant (fluindione)-aspirin
combination in patients with high-risk atrial fibrillation a ran-
domised trial (Fluindione, Fibrillation Auriculaire, Aspirin et
Contraste Spontane´; FFAACS). Cerebrovasc Dis 12(3):245–252
9. Edvardsson N, Juul-Moller SJ et al (2003) Effects of low-dose
warfarin and aspirin versus no treatment on stroke in a medium-
risk patient population with atrial fibrillation. J Intern Med
254(1):95–101
10. Douketis JD, Arneklev K, Goldhaber SZ, Spandorfer J, Halperin
F, Horrow J (2006) Comparison of bleeding in patients with
nonvalvular atrial fibrillation treated with ximelagatran or war-
farin. Arch Intern Med 166(8):853–859
11. Michel PL, Acar J (1998) Prothe`ses valvulaires me´caniques et
biologiques et traitements antithrombotiques. In: Samama MM,
Acar J (eds) Traitement Antithrombotique, Masson Edit, 3rd edn.
Paris, pp 143–175
12. Acar J, Michel PL, Iung B (1997) Les accidents thromboem-
boliques des prothe`ses valvulaires: incidence, pre´vention et
traitement en 1997. Sang Thromb Vaiss 9(3):172–178
13. Aupart M, Diemont F, Babuty S et al (1997) Re´sultats inter-
me´diaires avec la prothe`se valvulaire a` ailettes CarboMedics.
Arch Mal Coeur 9(4):457–462
14. Cannegieter SC, Rosendaal FR, Briet E (1994) Thromboembolic
and bleeding complications in patients with mechanical heart
valve prostheses. Circulation 89(2):635–641
15. Little SH, Massel DR (2003) Antiplatelet and anticoagulation for
patients with prosthetic heart valves. The Cochrane Database of
Systematic Reviews Issue (4):CD003464
16. Salem DN, Stein PD, Al-Ahmad A, Bussey HI, Horstkotte D,
Miller N, Pauker SG (2004) Antithrombotic therapy in valvular
heart disease—native and prosthetic: the seventh ACCP confer-
ence on antithrombotic and thrombolytic therapy. Chest 126(3
suppl):457S–482S
17. Dentali F, Douketis JD, Lim W, Crowther M (2007) Combined
aspirin–oral anticoagulant therapy compared with oral anticoag-
ulant therapy alone among patients at risk for cardiovascular
disease: a meta-analysis of randomized trials. Arch Intern Med
167(2):117–124
18. Massel D, Little SH (2001) Risks and benefits of adding anti-
platelet therapy to warfarin among patients with prosthetic heart
valves: a meta-analysis. J Am Coll Cardiol 37(2):569–578
19. Dale J, Myhre E, Loew D (1980) Bleeding during acetylsalicylic
acid and anticoagulant therapy in patients with reduced platelet
reactivity after aortic valve replacement. Am Heart J 99:746–752
20. Chesebro JH, Fuster V, Elveback LR, McGoon DC, Pluth JR,
Puga FJ, Wallace RB, Danielson GK, Orszulak TA, Piehler JM,
Schaff HV (1983) Trial of combined warfarin plus dipyridamole
or aspirin therapy in prosthetic heart valve replacement: danger of
aspirin compared with dipyridamole. Am J Cardiol 51(9):1537–
1541
21. Turpie AG, Gent M, Laupacis A, Latour Y, Gunstensen J, Basile
F, Klimek M, Hirsh J (1993) A comparison of aspirin with pla-
cebo in patients treated with warfarin after heart-valve
replacement. N Engl J Med 329(8):524–529
22. Altman R, Rouvier J, Gurfinkel E et al (1996) Comparison of
high-dose with low-dose aspirin in patients with mechanical heart
valve replacement treated with oral anticoagulant. Circulation
94:2113–2116
23. Meschengieser SS, Fondevilla C, Santarelli MT et al (1997) Low
intensity oral anticoagulation plus low dose aspirin versus high-
intensity oral anticoagulation alone: a randomized trial in patients
with mechanical prosthetic heart valves. J Thorac Cardiovasc
Surg 113:910–916
24. Laffort P, Roudaut R, Roques X, Lafitte S, Deville C, Bonnet J,
Baudet E (2000) Early and long-term (one-year) effects of the
association of aspirin and oral anticoagulant on thrombi and
morbidity after replacement of the mitral valve with the St. Jude
medical prosthesis: a clinical and transesophageal echocardio-
graphic study. J Am Coll Cardiol 35:739–746
25. Casais P, Meschengieser SS, Sanchez Luceros AG, Bermejo EI,
Lazzari MA (2002) Effect of low-dose aspirin on the international
normalized ratio variability in patients with mechanical heart
valve prostheses. Pathophysiol Haemost Thromb 32:155–157
26. Antiplatelet Trialists’ Collaboration (1994) Collaborative over-
view of randomised trials of antiplatelet therapy, I: prevention of
death, myocardial infarction, and stroke by prolonged antiplatelet
therapy in various categories of patients. Br Med J 308(6921):81–
106
27. Algra A, van Gijn J (1996) Aspirin at any dose above 30 mg
offers only modest protection after cerebral ischaemia. J Neurol
Neurosurg Psychiatry 60(2):197–199
28. Algra A, van Gijn J (1999) Cumulative meta-analysis of aspirin
efficacy after cerebral ischaemia of arterial origin. J Neurol
Neurosurg Psychiatry 66(2):255; Letter
29. Algra A, De Schryver ELLM, van Gijn J, Kappelle LJ, Koudstaal
PJ (2003) Oral anticoagulants versus antiplatelet therapy for
preventing further vascular events after transient ischemic attack
or minor stroke of presumed arterial origin. Stroke 34(1):234–235
428 A. Loualidi et al.
123
30. WARSS Investigators (2006) Comparison of warfarin versus
aspirin for the prevention of recurrent stroke or death: subgroup
analyses from the Warfarin-Aspirin Recurrent Stroke Study.
Cerebrovasc Dis 22(1):4–12
31. Moss AJ, Benhorin J (1990) Prognosis and management after a
first myocardial infarction. N Engl J Med 322(11):743–753
32. Kornowski R, Goldbourt U, Zion M, Mandelzweig L, Kaplinsky E,
Levo Y et al (1993) Predictors and long-term prognostic signifi-
cance of recurrent infarction in the year after a first myocardial
infarction. SPRINT Study Group. Am J Cardiol 72(12):883–888
33. Merlini PA, Bauer KA, Oltrona L, Ardissino D, Cattaneo M,
Belli C, Mannucci PM, Rosenberg RD (1994) Persistent activa-
tion of coagulation mechanism in unstable angina and myocardial
infarction. Circulation 90(1):61–68
34. Cohen M, Adams PC, Parry G, Xiong J, Chamberlain D, Wieczorek
I, Fox KA, Chesebro JH, Strain J, Keller C et al (1994) Combination
antithrombotic therapy in unstable rest angina and non-Q-wave
infarction in nonprior aspirin users. Primary end points analysis
from the ATACS trial. Antithrombotic Therapy in Acute Coronary
Syndromes Research Group. Circulation 89(1):81–88
35. CARS Investigators (1997) Randomized double blind trial of
fixed low-dose warfarin with aspirin after myocardial infarction.
Lancet 350:389–396
36. Anonymous (2000) Efficacy of oral anticoagulants compared
with aspirin after infrainguinal bypass surgery (The Dutch Bypass
Oral Anticoagulants or Aspirin Study): a randomised trial. Lancet
355(9201):346–351
37. The Organization to Assess Strategies for Ischemic Syndromes
(OASIS) Investigators (2001) Effects of long-term, moderate-
intensity oral anticoagulation in addition to aspirin in unstable
angina. J Am Coll Cardiol 37:475–484
38. Huynh T, The´roux P, Bogaty P, Nasmith J, Solymoss S (2001)
Aspirin, warfarin, or the combination for secondary prevention of
coronary events in patients with acute coronary syndromes and
prior coronary artery bypass surgery. Circulation 103(25):3069–
3074
39. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H (2002)
Warfarin, aspirin, or both after myocardial infarction. N Engl J
Med 347:969–974
40. van Es RF, Jonker JJ, Verheugt FW, Deckers JW, Grobbee DE
(2002) Antithrombotics in the Secondary Prevention of Events in
Coronary Thrombosis-2 (ASPECT-2) Research Group. Aspirin
and coumadin after acute coronary syndromes (the ASPECT-2
study): a randomised controlled trial. Lancet 360(9327):109–113
41. Fiore LD, Ezekowitz MD, Brophy MT et al (2002) Department of
Veterans Affairs Cooperative Studies Program Clinical Trial
comparing combined warfarin and aspirin with aspirin alone in
survivors of acute myocardial infarction: primary results of the
CHAMP study. Circulation 105:557–563
42. Herlitza J, Holmb J, Petersonc M, Karlsona BW, Evandera MH,
Erhardtb L, for the LoWASA study group (2004) Effect of fixed
low-dose warfarin added to aspirin in the long term after acute
myocardial infarction the LoWASA study. Eur Heart J 25:232–
239
43. Anand S, Yusuf S (2003) Oral anticoagulants in patients with
coronary artery disease. J Am Coll Cardiol 41(4 suppl):62S–69S
44. Rothberg MB, Celestin C, Fiore LD, Lawler E, Cook JR (2005)
Warfarin plus aspirin after myocardial infarction or the acute
coronary syndrome: meta-analysis with estimates of risk and
benefit. Ann Intern Med 143(4):241–250
45. Goldhaber SZ, Manson JE, Stampfer MJ, LaMotte F, Rosner B,
Buring JE, Hennekens CH (1992) Low-dose aspirin and
subsequent peripheral arterial surgery in the Physician’s Health
Study. Lancet 340(8812):143–145
46. Hirsh J, Dalen JE, Fuster V, Harker LB, Salzman EW (1992)
Aspirin and other anti-platelet drugs: the relationship between
dose, effectiveness, and side effects. Chest 102 (4 suppl):327S–
336S
47. Stroke Prevention in Atrial Fibrillation Investigators (1994)
Warfarin versus aspirin for prevention of thromboembolism in
atrial fibrillation: stroke prevention in Atrial Fibrillation II study.
Lancet 343(8899):687–691
48. Kretschmer G, Herbst F, Prager M, Sautner T, Wenzl E, Berla-
kovich GA, Zekert F, Marosi L, Schemper M (1992) A decade of
oral anticoagulant treatment to maintain autologous vein grafts
for femoropopliteal atherosclerosis. Arch Surg 127(9):1112–1115
49. Arfvidsson B, Lundgren F, Drott C et al (1990) Influence of
coumarin treatment on patency and limb salvage after peripheral
arterial reconstructive surgery. Am J Surg 159(6):556–560
50. de Smit P, van Urk H (1992) Dutch oral anticoagulation trial. Act
Chir Austr 24(1):5–7
51. Sarac TP, Huber TS, Back MR et al (1998) Warfarin improves
the outcome of infrainguinal vein bypass grafting at high-risk for
failure. J Vasc Surg 28(3):446–457
52. Johnson WC, Williford WO (2002) Benefits, morbidity, and
mortality associated with long-term administration of oral anti-
coagulant therapy to patients with peripheral arterial bypass
procedures: a prospective randomised study. J Vasc Surg
35(3):413–421
53. Chesney CM, Elam MB, Herd JA, Davis KB, Garg R, Hun-
ninghake, Kennedy JW, Applegate WB (2000) Effect of niacin,
warfarin, and antioxidant therapy on coagulation parameters in
patients with peripheral arterial disease in the arterial disease
multiple intervention trial (ADMIT). Am Heart J 140(4):631–636
54. The Warfarin Antiplatelet Vascular Evaluation Trial Investigators
(2007) Oral anticoagulant and antiplatelet therapy and peripheral
arterial disease. N Engl J Med 357(3):217–227
55. Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K
et al (2006) Guidelines for prevention of stroke in patients with
ischemic stroke or transient ischemic attack. Stroke 37(2):577–
617
56. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P (2004)
Antithrombotic and thrombolytic therapy for ischemic stroke: the
seventh ACCP conference on antithrombotic and thrombolytic
therapy. Chest 126(3 suppl):483S–512S
57. Eikelboom JW, Hirsh L (2007) Combined antiplatelet and anti-
coagulant therapy: clinical benefits and risks. J Thromb Haemost
5(1 Suppl):255–263
58. Donaldson DR, Salter MC, Kester RC et al (1985) The influence
of platelet inhibition on the patency of femoro-popliteal Dacron
bypass grafts. J Vasc Surg 19(4)224–230
59. Goldman MD, McCollum CN (1984) A prospective randomised
study to examine the effect of aspirin plus dipyridamole on the
patency of prosthetic femoro-popliteal grafts. J Vasc Surg 18(4):
217–221
60. Green RM, Roedersheimer LR, DeWeese JA (1982) Effects of
aspirin and dipyridamole on expanded polytetrafluoroethylene
graft patency. Surgery 92(6):1016–1026
61. Kohler TR, Kaufman JL, Kacoyanis GP et al (1984) Effect of
aspirin and dipyridamole on the patency of lower extremity
bypass grafts. Surgery 96(3):462–466
62. McCollum C, Alexander C, Kenchington G, Franks PJ, Green-
halgh RM (1991) Anti-platelet drugs in femoropopliteal vein
bypasses: a multicentre trial. J Vasc Surg 13(1):150–162
Combination therapy of VKA and aspirin 429
123
